ArticleHaematologica2019

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.

Georgios Nteliopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.